Triptolide cooperates with cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer

Pancreas

Volumn 41, Issue 7, 2012, Pages 1029-1038

  Zhu, Wenbo ^a   Li, Jingjie ^a,b   Wu, Sihan ^a   Li, Shifeng ^a   Le, Liang ^a   Su, Xingwen ^a   Qiu, Pengxin ^a   Hu, Haiyan ^c   Yan, Guangmei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b The Second Affiliated Hospital   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

apoptosis; cisplatin; gemcitabine resistant pancreatic cancer; HSP27; triptolide

Indexed keywords

CISPLATIN; GEMCITABINE; HEAT SHOCK PROTEIN 27; SMALL INTERFERING RNA; TRIPTOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY RESISTANCE; TUMOR REGRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DITERPENES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPOXY COMPOUNDS; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHENANTHRENES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84865862229     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31824abdc0     Document Type: Article

References (53)

1. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109-1113.
2. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163-172.
3. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs. 2006;15:1395-1410.
4. King RS. Gemcitabine. New first-line therapy for pancreatic cancer. Cancer Pract. 1996;4:353-354.
5. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
6. Ina S, Hirono S, Noda T, et al. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance. Pancreas. 2010;39:473-485.
7. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, et al. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35:335-339.
8. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology. 2001;60:8-18.
9. Laskowska E. Small heat shock proteinsVrole in apoptosis, cancerogenesis and diseases associated with protein aggregation [in Polish]. Postepy Biochem. 2007;53:19-26.
10. Garrido C, Mehlen P, Fromentin A, et al. Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. Eur J Biochem. 1996;237:653-659.
11. Yang YX, Sun XF, Cheng AL, et al. Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol. 2009;135:181-189.
12. Langdon SP, Rabiasz GJ, Hirst GL, et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res. 1995;1:1603-1609.
13. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003;63:6174-6177.
14. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 2000;60:7099-7105.
15. Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma. 2001;42:253-265.
16. Kiviharju TM, Lecane PS, Sellers RG, et al. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002;8:2666-2674.
17. Miyata Y, Sato T, Ito A. Triptolide, a diterpenoid triepoxide, induces antitumor proliferation via activation of c-Jun NH2-terminal kinase 1 by decreasing phosphatidylinositol 3-kinase activity in human tumor cells. Biochem Biophys Res Commun. 2005;336:1081-1086.
18. Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003;2:65-72.
19. Pigneux A, Mahon FX, Uhalde M, et al. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp Hematol. 2008;36:1648-1659.
20. Chang WT, Kang JJ, Lee KY, et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem. 2001;276:2221-2227.
21. Fidler JM, Li K, Chung C, et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther. 2003;2:855-862.
22. Westerheide SD, Kawahara TL, Orton K, et al. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem. 2006;281:9616-9622.
23. Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem. 1999;274:13443-13450.
24. Rejiba S, Wack S, Aprahamian M, et al. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci. 2007;98:1128-1136.
25. Xia Y, Liu Y, Wan J, et al. Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem. 2009;52:6083-6096.
26. Wan CK, Wang C, Cheung HY, et al. Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett. 2006;241:31-41.
27. Carter BZ, Mak DH, Schober WD, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006;108:630-637.
28. Garrido C, Gurbuxani S, Ravagnan L, et al. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun. 2001;286:433-442.
29. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
30. Boeck S, Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol. 2008;4:41-50.
31. Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard? Oncology (Williston Park). 2008;22:1176-1183; discussion 1190, 1192, 1196.
32. Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001;20:8009-8018.
33. Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 2009;15:1686-1697.
34. Lee KY, Chang W, Qiu D, et al. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem. 1999;274:13451-13455.
35. Carter BZ, Mak DH, Schober WD, et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008;111:3742-3750.
36. Lee KY, Park JS, Jee YK, et al. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)Yinduced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med. 2002;34:462-468.
37. Borja-Cacho D, Yokoyama Y, Chugh RK, et al. TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells. J Gastrointest Surg. 2010;14:252-260.
38. Matsui Y, Watanabe J, Ikegawa M, et al. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. Oncogene. 2008;27:4603-4614.
39. Phillips PA, Dudeja V, McCarroll JA, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007;67:9407-9416.
40. Choi JH, Oh SY, Kwon HC, et al. Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis. Cancer Res Treat. 2008;40:22-26.
41. He JC, Lu TC, Fleet M, et al. Retinoic acid inhibits HIV-1Yinduced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol. 2007;18:93-102.
42. Yamamoto K, Okamoto A, Isonishi S, et al. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett. 2001;168:173-181.
43. Zhang Y, Shen X. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res. 2007;13:2855-2864.
44. Shamovsky I, Nudler E. New insights into the mechanism of heat shock response activation. Cell Mol Life Sci. 2008;65:855-861.
45. Voellmy R. On mechanisms that control heat shock transcription factor activity in metazoan cells. Cell Stress Chaperones. 2004;9:122-133.
46. Cotto JJ, Morimoto RI. Stress-induced activation of the heat-shock response: cell and molecular biology of heat-shock factors. Biochem Soc Symp. 1999;64:105-118.
47. McCollum AK, Lukasiewicz KB, Teneyck CJ, et al. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther. 2008;7:3256-3264.
48. Love S, King RJ. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer. 1994;69:743-748.
49. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 2007;31:1345-1350.
50. Taba K, Kuramitsu Y, Ryozawa S, et al. KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy. 2010;57:12-16.
51. Garrido C, Ottavi P, Fromentin A, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res. 1997;57:2661-2667.
52. Schafer C, Ross SE, Bragado MJ, et al. A role for the p38 mitogen-activated protein kinase/Hsp 27 pathway in cholecystokinin-induced changes in the actin cytoskeleton in rat pancreatic acini. J Biol Chem. 1998;273:24173-24180.
53. Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol. 2000;2:645-652.